CVD Risk Similar for Metformin + Insulin or Sulfonylureas

This article originally appeared here.
Share this content:
CVD Risk Similar for Metformin + Insulin or Sulfonylureas
CVD Risk Similar for Metformin + Insulin or Sulfonylureas

FRIDAY, July 17, 2015 (HealthDay News) -- For patients with type 2 diabetes, the risk of myocardial infarction (MI) or stroke is similar for treatment with insulin or sulfonylureas in combination with metformin, according to a study published online July 14 in Diabetes, Obesity and Metabolism.

James S. Floyd, M.D., from the University of Washington in Seattle, and colleagues conducted a population-based case-control study to examine the risks of MI and stroke associated with sulfonylureas and insulin used in combination with metformin. Cases had type 2 diabetes and used metformin plus insulin or sulfonylureas at the time of a first MI or stroke, while controls used the same treatment combinations and were sampled from the same population. Medical records were reviewed to validate MI and stroke diagnosis and potential confounders.

The researchers found that the risk of MI or stroke was similar for metformin + insulin and metformin + sulfonylureas (odds ratio, 0.98; 95 percent confidence interval, 0.63 to 1.52). The precision of the estimate was improved on meta-analysis with another observational study (relative risk, 0.92; 95 percent confidence interval, 0.69 to 1.42).

"Current evidence suggests that there may not be large differences in cardiovascular risk associated with the use of insulin or sulfonylureas when used in combination with metformin," the authors write.

One author disclosed financial ties to Zoll LifeCor and Johnson & Johnson.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »